IL22 and myeloid sarcoma: We analyzed a new cohort of 28 MS patients (12 treated with natalizumab, since these patients might have enhanced numbers of autoreactive T cells in blood [8, 32] and 16 untreated) and 13 healthy controls (Table S3) by multicolor analysis with simultaneous detection of IFNγ, IL-17A, and IL-22.